Related by context. All words. (Click for frequent words.) 81 Licensing Pact 78 Signs Licensing Agreement 78 Distribution Pact 75 Signs License Agreement 75 Announces License Agreement 75 Announces Licensing Agreement 74 Announce Exclusive 74 Sign Licensing Agreement 74 Signs Licensing 74 Ink Deal 74 Inks Deal 73 Sign License Agreement 73 Inks Deal With 73 Enter Into 73 Inks Deals 73 Inks Distribution 73 Inks Exclusive 73 Signs Distribution 72 Expand Relationship 72 Strikes Deal 72 Signs Exclusive 72 Announce License Agreement 72 Signs Deal 72 License Pact 72 Patent Licensing Agreement 72 Inks Pact 71 Relaunches 71 Enters Agreement 71 Licensing Agreement 71 Announce Licensing Agreement 71 Scoops Up 70 Spins Off 70 Inks Multi 70 Acquires Exclusive 70 Snaps Up 70 Extends Reach 70 Signs Agreement 70 Announce Joint Venture 70 Endorsement Deal 70 Settle Patent Litigation 70 Announce Collaboration 70 Wins Approval 70 Enters Into Licensing Agreement 69 Announce Agreement 69 Patent Dispute 69 Expands Portfolio 69 Infringement Case 69 Extends Collaboration 69 Gobbles Up 69 Worldwide Licensing Agreement 69 Signs Pact 69 ADDING MULTIMEDIA 69 Enters Strategic 69 Receives Patent 69 Develop Novel 69 Submits Application 69 Patent Infringement Suit Against 69 Sponsorship Deal 69 Expand Collaboration 69 Extend Partnership 69 Rebrands 69 Restructures 69 Signs Long Term 69 Officially Launches 69 Expand Into 69 Announce Licensing 69 Enters Into Exclusive 69 Aquires 69 Discontinues 68 Enters Exclusive 68 Settle Dispute 68 Files IND 68 Patent Suit 68 Complete Merger 68 Enters Into Agreement 68 Patent Lawsuit 68 Settle Patent 68 Enters Into 68 Collaborates With 68 Settles Litigation 68 Achieves Milestone 68 Completes Merger 68 Settles Patent Litigation 68 Secures Exclusive 68 Inks Licensing Deal 68 Inks Agreement 68 Signs Agreements 68 Bulks Up 68 Legal Dispute 68 Expands Distribution 68 Anounces 68 Enters Into License Agreement 68 Reaches Milestone 68 Files Patent 68 Settle Litigation 68 Broadens Its 68 Annouces 68 Ink Pact 68 Enters Joint Venture 68 Completes Transaction 68 Awarded Patent 68 Shares Surge 68 FDA Clears 68 Shares Soar 67 Announces Termination 67 Exclusive License 67 Inks License 67 Unwraps 67 Buys Majority Stake 67 Forges Ahead 67 Enters Into Partnership 67 Secures Additional 67 Patent Infringement Suit 67 Biotech Firm 67 Patent Infringement Case 67 Acquire Assets 67 Distribution Agreements 67 Infringed 67 Announces Definitive Agreement 67 Slashes Prices 67 Continues Momentum 67 Secures Financing 67 Largest Ever 67 Obtains License 67 Momentum Continues 67 Settle Patent Dispute 67 Extends Relationship 67 Finalize Agreement 67 Milestone Payment 67 Jointly Develop 67 Cross Licensing Agreement 67 Reach Agreement 67 Renews Agreement 67 Amends Agreement 67 Announces FDA Clearance 67 Signs Joint Venture 67 Begins Shipment 67 Unveils Latest 67 Expands Into 67 Takes Stake 67 Latest Addition 67 Subsidiary Enters 67 Withdraws Offer 67 Reaches Agreement 66 Terminates Agreement 66 Hits Milestone 66 Announces Signing 66 Slashes Price 66 Announce Partnership 66 Amps Up 66 Secures Contract 66 Stockholders Approve Merger 66 Jointly Announce 66 Elevates 66 Expands Relationship 66 Receives Milestone Payment 66 Strategic Relationship 66 Obtains Exclusive Rights 66 Announce Settlement 66 Nears Deal 66 Enters Into Joint Venture 66 Shows Promise 66 Completes Patient Enrollment 66 Launches Innovative 66 Announce Collaboration Agreement 66 Extends Contract 66 Joins Forces 66 Multimillion Dollar 66 Signs Multi 66 Receives Orphan Drug Designation 66 Exercises Option 66 Cuts Costs 66 Attains 66 Strengthens Position 66 Seeks Approval 66 Gets Approval 66 Patent Infringement Lawsuit Against 66 Approve Merger 66 Continues Expansion 66 Announces Sponsorship 66 Enters Into Strategic 66 Awarded Multi 66 Monetizes 66 Patent Infringement Lawsuit 66 Offers Glimpse 66 Concludes Acquisition 66 Develop Next Generation 66 Abandons Plans 66 Trademark Dispute 66 Unveils Innovative 66 Settles Patent Dispute 66 Expands Internationally 66 Launches Unique 66 Shares Climb 66 Spins Out 66 Forms Joint Venture 66 Sell Itself 66 Trademark Lawsuit 66 Antitrust Suit 66 Announces Immediate Availability 66 Shareholders Approve Merger 65 Jointly Offer 65 Co Branded 65 Acquire Controlling Interest 65 Announce Merger Agreement 65 Completes Tender Offer 65 Expands Scope 65 Amplifies 65 Reseller Agreement 65 Signs MOU 65 Terminates Contract 65 Begins Shipping 65 Announces Initiation 65 Signs Contract 65 Slims Down 65 Settles Charges 65 Deal Collapses 65 Outlines Strategy 65 Terminate Merger Agreement 65 Sign Pact 65 Extends Offer 65 Unveils Next Generation 65 Refocuses 65 Buys Stake 65 Halts Production 65 Extend Relationship 65 Buy Privately Held 65 Sells Stake 65 Re Ups 65 Becomes Largest 65 Maker Sues 65 Confirms Commitment 65 Distribution Agreement 65 Arthritis Drug 65 Ups Ante 65 Sign Definitive Agreement 65 Buys Into 65 Extend Collaboration 65 Makes Bid 65 Settles Suit 65 Makes Debut 65 Outsells 65 BioSante Pharmaceuticals Announces 65 Receives FDA Clearance 65 Signs Lease 65 Multiyear Deal 65 Builds Momentum 65 Closes Merger 65 Announces Intent 65 Files Patent Application 65 Patent Lawsuit Against 65 Strengthens Its 65 Further Strengthens 65 Settles Dispute 65 Beefs Up 65 Expands Presence 65 Completes Financing 65 Announce Expanded 65 Patent Suit Against 65 Equity Stake 65 News Unternehmensnachrichten 65 Starts Shipping 65 Successfully Completes Tender Offer 65 Buyout Bid 65 Receives Approval 65 Taro Receives 65 Chalks Up 65 Clears Path 65 Diversifies 65 Q1 Loss Widens 65 Launches Groundbreaking 65 Finalizes Deal 65 Relaunches Website 65 Forges Partnership 65 Announce Completion 65 Consummates 65 Closes Financing 65 Retrans Deal 65 Minority Stake 65 Merges 65 Countersues 65 Wins Coveted 65 Enters Negotiations 65 Acquire Stake 65 Files Countersuit Against 65 Expands Relationship With 65 Terminates 65 Patent Issued 65 Milestone Payments 65 Subsidiary Signs 64 Completes Acquisition 64 Secures Long Term 64 Merger Creates 64 Amend Merger Agreement 64 Vid Biz 64 Completes Reverse Merger 64 Jumps Higher 64 Shareholders Approve 64 Stock Soars 64 Commercializes 64 Expands Availability 64 Resolve Dispute 64 Website Launched 64 Announce Merger 64 Posts Strong 64 Asset Swap 64 Forms Strategic 64 Platform Enables 64 Exclusive Distribution 64 Sells Itself 64 Acquires 64 Creates Buzz 64 Expands Offerings 64 Terminate Agreement 64 Expands Capabilities 64 Licensing Agreements 64 Strengthens Commitment 64 Osteoporosis Drug 64 Establish Joint Venture 64 Q1 Loss Narrows 64 Licenses Novel 64 Ceases 64 Reach Settlement 64 Finalizes Acquisition 64 Q3 Loss Narrows 64 Raises Bid 64 Receives Approvable Letter 64 Ups Bid 64 Achieves Significant 64 Exclusive Licensing Agreement 64 FDA Okays 64 Completes Merger With 64 Reaffirms Commitment 64 Patent Ruling 64 Resolves Dispute 64 Posts Wider Loss 64 Reaches Deal With 64 Seeks Buyer 64 Formalizes 64 Awarded Patents 64 Reorganizes 64 Board Authorizes 64 Q3 Loss Widens 64 Injunction Against 64 Reacquires 64 Announces Expanded 64 Becomes Latest 64 Net Loss Narrows 64 Announce Availability 64 Finalizes 64 Merger Talks 64 Patent Infringement Litigation 64 Renews Contract 64 Commercialize 64 Morphs Into 64 FTC Clears 64 Keeps Growing 64 Revamps Website 64 Acquire Majority Stake 64 Joins Hands 64 Debuts Next Generation 64 Withdraws Application 64 Settle Lawsuit 64 Settle Dispute Over 64 Bolsters 64 Quadruples 64 Achieves Record 64 Infringement Suit 64 HSR Waiting Period 64 Introduces Enhanced 64 Reports Positive 64 Increases Stake 64 Executes Agreement 64 Ventures Invests 64 Announces Acquisition 64 Signs Merger Agreement 64 Net Loss Widens 64 Settles Lawsuit 64 Furthers 64 Completes Enrollment 64 Generic Version 64 Marks Milestone 64 Demonstrates Commitment 64 Celebrates Successful 64 Long Awaited 64 Announces Enhancements 64 Cooperates 64 Sews Up 64 Eagerly Awaited 64 COMUNICADO 64 Patent License Agreement 64 Signs LOI 64 PHOTO ADVISORY 64 Extends Tender Offer 64 Settles Patent 64 Announces Favorable 64 Finalizes Agreement 64 Makes Waves 64 Finalises 64 Acacia Subsidiary 64 Raises Stake 64 Join Forces 64 Rolled Out 64 Files Registration Statement 64 Completes Asset 63 Takeover Speculation 63 Initiates Phase II 63 Unveils Newest 63 Announce Strategic 63 Misonix Announces 63 Psoriasis Drug 63 Completes Integration 63 Completes Purchase 63 Expands Reach 63 Sweetens 63 Notches Up 63 Losses Widen 63 Posts 1Q Profit 63 Receives Favorable 63 Delivers Next Generation 63 Expands Capacity 63 Officially Launched 63 Recieves 63 Reinvents Itself 63 Narrows 4Q Loss 63 Settles Patent Suit 63 Content Bits 63 Reach Deal 63 Initiates Dosing 63 Terminates Merger Agreement 63 Introduces Revolutionary 63 Dramatically Expands 63 Positions Itself 63 Wins Lawsuit Against 63 CFO Resigns 63 Initiates Enrollment 63 Suit Vs 63 Extend Contract 63 FDA Accepts 63 Launches Next Generation 63 Goes Viral 63 Revolutionizes 63 Ramps Up 63 Changes Name 63 Negotiates 63 Formally Launches 63 Gives Sneak Peek 63 Patent Covering 63 Controlling Stake 63 Infringes 63 Licenses Patents 63 Collaborates 63 Acquires Stake 63 Moves Forward 63 Announce Definitive Agreement 63 Buyout Talks 63 Signs Reseller Agreement 63 Earns Milestone Payment 63 Obtains 63 Announces Launch 63 Revitalizes 63 Ad Supported 63 Reduces Debt 63 Reaches Deal 63 Enters Into Definitive Agreement 63 Unlocks 63 Repositions 63 Takeover Talks 63 Completes Transition 63 Milestone Reached 63 Renews Multi 63 Buy Stake 63 Newest Addition 63 Offers Peek 63 Contract Extension 63 Reveals Positive 63 Undisclosed Amount 63 Regains Compliance 63 Loss Widens 63 Leaps Ahead 63 Streamlines Operations 63 Unveils Revolutionary 63 Announces Successful Completion 63 GameZone News 63 Announce Receipt 63 FCC Approves 63 Agreement Reached 63 Antitrust Probe 63 Receives Orphan Drug 63 Much Anticipated 63 Obtains Exclusive License 63 Takes Majority Stake 63 Exec Says 63 Suit Against 63 Enters Into Distribution 63 Stockholders Approve Acquisition 63 Introduces Innovative 63 Completes Initial 63 Inches Closer 63 Unveils Expanded 63 Significantly Expands 63 Introduces Next Generation 63 Layoffs Hit 63 Enrolls First 63 FDA Approves 63 Entry Into 63 Drug Candidate 63 Withdraws Proposal 63 Boosts Stake 63 Extends Commitment 63 Announce Launch 63 Fifth Consecutive 63 Dethrones 63 Significantly Increases 63 Cholesterol Drug 63 Wins Patent Infringement 63 Renews Sponsorship 63 Initiates Clinical Trials 63 Announcement Regarding 63 Contract Dispute 63 Inks Long Term 63 Accepted Into 63 Newly Acquired 63 Buy Majority Stake 63 Buyout Offer 63 Speeds Up 63 Generic Versions 63 Improves Survival 63 More Than Doubles 63 Receives Notification 63 Enlarges 63 Fortifies 63 Renews Partnership 63 Inks Licensing Agreement 63 Announces Intention 63 Plans Job Cuts 63 Long Term Relationship 63 Global Reseller Agreement 63 Successfully Closes 63 Losses Narrow 63 Receives CE Marking 63 Antitrust Lawsuit 63 Posts Profit 63 Taps Into 63 1Q Loss Widens 63 Gets Bigger 63 Receives Favorable Ruling 63 Revamps 63 Q2 Loss Narrows 63 Merge Healthcare Announces 63 Introduces Breakthrough 63 Receive Milestone Payment 63 Signs Endorsement 63 Posts Solid 63 Contract Extensions 62 Remains Committed 62 Patient Enrollment 62 Pulls Plug 62 Strips Down 62 Mutually Agree 62 Significant Milestone 62 Completes Purchase Of 62 Gains Ground 62 Confirms Talks 62 Walks Away 62 Merge Creating 62 Files Patent Infringement 62 Makes Splash 62 Receives Unsolicited 62 Signs Option Agreement 62 Celebrates Opening 62 Submits NDA 62 Reaches Settlement 62 Receives Positive 62 Jointly Launch 62 Closes Acquisition 62 Goes Retro 62 Offers Unprecedented 62 Migraine Drug 62 Moves Into 62 Files Suit Against 62 Celebrates Anniversary 62 Lauches 62 Loses Lawsuit 62 Acquires Majority Stake 62 Shares Plummet 62 MultiVu Video Feed 62 Breaks Barriers 62 Racks Up 62 Announces Discontinuation 62 Announces Issuance 62 Exec Sees 62 Q2 Loss Widens 62 Lupus Drug 62 Presents Positive 62 Antitrust Case 62 Restate Financials 62 Extend Reach 62 Enters Into Letter 62 Raise Stake 62 Enhances User Experience 62 Goes Bust 62 Renegotiates 62 Opens Door 62 Exclusive Licensee 62 Rheumatoid Arthritis Drug 62 Jaw Dropping 62 Gets Clearance 62 Expands Globally 62 Schizophrenia Drug 62 Antes Up 62 Settle Lawsuit Over 62 Reignites 62 Third Consecutive 62 Obtains Approval 62 Could Revolutionize 62 Ekes Out 62 3Q Loss Widens 62 Coughs Up 62 Announces Tentative Approval 62 Aligns 62 Secures 62 Becomes Newest 62 Launches Expanded 62 Accelerates Expansion 62 Contract Renewal 62 Gets Makeover 62 Launches Redesigned Website 62 Extends Relationship With 62 Announces Job Cuts 62 Shareholders Approve Acquisition 62 Shifts Gears 62 Be Acquired 62 Launches Enhanced 62 More Than Triples 62 Announces Publication 62 Seeks Damages 62 Acquires Controlling Interest 62 Newly Launched 62 Beats Forecasts 62 Reports Wider Loss 62 Majority Stake 62 Broadens 62 Deliver Next Generation 62 1Q Loss Narrows 62 Reinvents 62 Cross License Agreement 62 Q4 Loss Narrows 62 Moves Ahead 62 E3 Lineup 62 Announces Dismissal 62 Lowers Guidance 62 FY# Loss Narrows 62 Receives Clearance 62 Serves Up 62 Sales Soar 62 Profits Soar 62 Lung Cancer Drug 62 Narrows Loss 62 Progresses 62 Solidifies 62 Shares Slump 62 Significantly Reduces 62 Exec Joins 62 Q4 Profit Plunges 62 Completes Sale 62 Outshines 62 Regains Compliance With 62 Busts Out 62 Signs Definitive 62 Leaps Into 62 Buyback Plan 62 Strengthens Leadership 62 Sets Sail 62 Earnings Cheat Sheet 62 Steps Into 62 Submits Bid 62 Complaint Against 62 Submits Biologics License Application 62 Offers Unique 62 Receives Notice 62 Attracts Attention 62 Announce Intention 62 Q2 Adj 62 Downsizes 62 Decodes 62 Epilepsy Drug 62 Abandons Bid 62 Settle Suit 62 Strengthens Balance Sheet 62 Gets Sued 62 Meets Primary Endpoint 62 Exec Leaves 62 Wins Contract 62 Deliver Integrated 62 Regains Full 62 Sells Shares 62 Successfully Completes 62 Makes Strides 62 Profit Doubles 62 Achieves Record Sales 62 Deliver Powerful 62 Win Prestigious 62 Pumps Up 62 Prostate Cancer Vaccine 62 Sharpens Focus 62 Showcases Innovative 62 Resubmits 62 Secures Funding 62 Officially Confirmed 62 Doubles Capacity 62 Closes Acquisition Of 62 IPhone App 62 Begins Rollout 62 Entered Into 62 Acquire Privately Held 62 Launches Website 62 Regulatory Clearance 62 Receives Notice Regarding 62 Successful Completion 62 To Be Replaced 62 Update# 62 Debuts 62 Gives Boost 62 Profit Beats Estimates 62 Edges Closer 62 Sales Surpass 62 Dev Kits 62 Kick Starts 62 Present Preclinical Data 62 Waves Goodbye 62 Subsidiary Wins 62 Rolls Out 62 Expands 62 Appoints Seasoned 62 Regains 62 Annouce 62 Renews 62 Announces Commencement 62 Doubles Size 62 Youngest Ever 62 Tops Charts 62 Multimillion Dollar Contract 62 Flagship Product 62 Has Entered 62 Completes Private Placement 62 Widely Available 62 Profits Plunge 62 Announces Expansion 62 Inks Contract 62 Develops Innovative 62 Exploring Strategic Alternatives 62 Acquires Assets 62 Boosts Profits 62 Goes Offline 62 Files Shelf Registration Statement 61 Reports Receipt 61 Has Received 61 Wider Loss 61 Retools 61 Trims Loss 61 Releases Next Generation 61 Blazes Trail 61 Announces Proposed 61 Blood Thinner 61 Enters Into Multi 61 Suit Settled 61 Posts 4Q Profit 61 Loss Narrows 61 Officially Becomes 61 Completes Successful 61 Soars Into 61 Faces Lawsuit 61 Achieves Highest 61 Announces Shareholder Approval 61 Signs Definitive Agreements 61 Subsidiary Acquires 61 Posts Record 61 Trots Out 61 Patent Suits 61 Strengthens Relationship 61 Settlement Reached 61 Introduces Powerful 61 Sees Positive 61 Sweetens Bid 61 Announces Upcoming 61 Hits Shelves 61 Reaches Pact 61 Drug Shows Promise 61 Itself Into 61 Receives SFDA Approval 61 Copyright Infringement 61 Outbids 61 Acquirer Company 61 Revs Up 61 Broadens Scope 61 Foray Into 61 Announces Receipt 61 Divests 61 Picks Up 61 Updates Status 61 Posts Loss 61 Remains Neutral 61 Smashing Success 61 Gets Nod 61 Surpasses Expectations 61 Announces Formation 61 Settles Claim 61 Announces Addition 61 Obtains Exclusive 61 Boosts Outlook 61 Explore Strategic Alternatives 61 FY# Loss Widens 61 Awaits Approval 61 Offers Customized 61 ΞΕΝΗ ΔΗΜΟΣΙΕΥΣΗ ΑΝΑΚΟΙΝΩΣΗInfosys Finacle 61 Commences Cash 61 Q2 Profit Slips 61 Acquisition Spree 61 Sell Stake 61 Beats Expectations 61 Evolves 61 Signs Definitive Agreement 61 Wider Audience 61 Sixth Consecutive 61 Discloses 61 Significantly Expand 61 Hostile Bid 61 Gout Drug 61 Nearing Deal 61 Settles Dispute With 61 Restructures Debt 61 Value Added Reseller Agreement 61 Dives Into 61 Extends Leadership 61 Stays Neutral 61 Offers Affordable 61 Penetrates 61 Dispute Continues 61 Preliminary Injunction Against 61 Scraps Plans 61 Multi Billion Dollar 61 Issues Statement Regarding 61 Takes Reins 61 Celebrates Birthday 61 Surges Ahead 61 Successfully Launches 61 Leading Provider 61 Settle Lawsuits 61 Receives Tentative Approval 61 Enters Into LOI 61 Finalizes Contract 61 Provides Update Regarding 61 Blasts Off 61 Presents Preclinical Data 61 Voluntarily Withdraw 61 Officially Released 61 Inks MOU 61 ONN.tv Report 61 Trademark Suit 61 Unloads 61 Concludes Successful 61 Realigns 61 Reduces Stake 61 Signs Letter 61 Q4 Loss Widens 61 FDA Panel Recommends 61 Posts 2Q 61 Signs Multiyear 61 Unsolicited Tender Offer 61 Extends Sponsorship 61 Releases Upgraded 61 Receives Order 61 Snapped Up 61 Being Studied 61 Significantly Improves 61 Gets Serious 61 Enters Final 61 Adds Depth 61 Previously Announced 61 Issued Patent 61 Ups Stake 61 Exclusive License Agreement 61 Future Uncertain 61 Secures Patent 61 Movie Downloads 61 Makes Headway 61 Guides Inline 61 Derma Sciences Announces 61 Holders Approve 61 Wins Injunction Against 61 Faces Suit 61 Significantly Enhances 61 Now Available Exclusively 61 Continues Winning Streak 61 Breaks Record 61 Reacquire 61 Report Analyzes 61 Mulls Options 61 Plugs Into 61 Proudly Announces 61 Expand Presence 61 Lawsuit Dismissed 61 Percent Stake 61 Creates Unique 61 Announce Signing 61 Considers Bid 61 Receives Funding 61 Affirms Commitment 61 Q1 Profit Surges 61 FDA Approvals 61 Announces Organizational Changes 61 Boosts Productivity 61 Widens 61 Jointly Developed 61 Important Milestone 61 Certifies 61 Sees Strong 61 Moves Towards 61 #.#B Bid 61 Changes Afoot 61 Feud Continues 61 Confirms Receipt 61 Announces Successful 61 Commences Tender Offer 61 Deliver Innovative 61 Receives Regulatory 61 Beats Estimates 61 Validates 61 Files Lawsuit Against 61 Million Financing 61 Integra LifeSciences Announces 61 Posts Quarterly 61 ots.CorporateNews 61 Ratifies 61 Reach Settlement Agreement 61 Renews Exclusive 61 Profit Soars 61 Board Unanimously Rejects 61 Suffers Setback 61 Q3 Adj 61 Completes Sale Of 61 Earns Highest 61 Packs Punch 61 Successful Launch 61 Multi Platform 61 Shareholder Opposes 61 Satisfies 61 Extends Deadline 61 Closes Private Placement 61 Significant Milestones 61 Announce Early Termination 61 Clears Way 61 Mulls Sale 61 Announces Private Placement 61 Patience Pays Off 61 Successfully Complete 61 Reaches Settlement Agreement 61 Closes Previously Announced 61 Settles Lawsuits 61 Narrows Losses 61 Negotiations Continue 61 Paves Way 61 Million Dollar Contract 61 Wins Prestigious 61 Bids Adieu 61 Announces Definitive Merger 60 Shares Plunge 60 Sees Profit 60 Q2 Profit Soars 60 Has Emerged 60 Pulls Out 60 Denies Bid 60 Patent Upheld 60 Shareholders Reject 60 Prescribes 60 Boosts Capacity 60 Hiring Spree 60 Divulges 60 Receives Tentative FDA 60 Profits Plummet 60 Drug Fails 60 Court Upholds 60 Receives Notice From 60 Gains Momentum 60 Becomes Exclusive 60 Files Suit 60 Raises Guidance 60 Profits Drop 60 Supply Agreements 60 Nearly Triples 60 Bows Out 60 Expanding Presence 60 Provide Comprehensive 60 Locks Down 60 Wins Summary Judgment 60 RR Donnelley Awarded 60 Analyst Predicts 60 Much Awaited